Michael Mayne was born and raised in Canada. He earned his PhD at the University of Toronto, and completed fellowship training at the University of Manitoba Medical School and the National Institutes of Health in Bethesda MD. His background is pharmacology and cell biology. 

He was the founding Research Director of the National Research Council Institute in his home province of Prince Edward Island. In 2007, he led the development of Provincial Economic Development Plan and served as Deputy Minister of Industry on PEI. During his tenure, he helped strengthen the local bio-cluster which now boasts over 2,500 jobs and generates $500M in annual sales.

From 2011-2017, he served as Deputy Minister of Health on PEI and subsequently, the CEO of Health PEI. He worked directly for the Premiers of Canada as the co-lead of the Council of the Federation Working Group on HealthCare Innovation. During his tenure in this role, he helped guide the process that the provinces in Canada now use for pCPA negotiations and generic drug pricing.

Dr. Mayne left the public sector in 2017. As an independent consultant, he has worked with global pharmaceutical companies to aid in reimbursement strategies and market access. In 2020, Dr. Mayne founded Remidose Aerosols Inc (www.remidose.com) which is now the only global manufacturer of GMP metered dose cannabis inhalers. Remidose inhalers are now sold in Canada, United States, and the Australian medical cannabis marketplace with expansion in 2026 into the UK and EU.